July 12, 2011 —Crizotinib, a new targeted drug aimed at certain patients with nonsmall-cell lung cancer (NSCLC), is expected to be approved before the end of the year. The drug targets an ALK ...

Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma The 2-year event-free survival (EFS) is 76.8% (95% CI, 68.5 to 88.1) and the 2-year overall ...

Adjuvant crizotinib (Xalkori) failed to improve disease-free survival (DFS) in patients with surgically resected early-stage ALK-positive non-small cell lung cancer (NSCLC), the phase III ECOG-ACRIN ...

Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with ...

Discover comprehensive details about Crizotinib, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children’s Oncology Group Before anaplastic lymphoma kinase (ALK) inhibitors, treatment ...

Doctors are reluctant to read too much into promising results from small clinical trials of cancer drugs. No point getting excited when so often drugs don’t look as hot after being tested in a larger ...

Please provide your email address to receive an email when new articles are posted on . Crizotinib is a new tyrosine kinase inhibitor with action against anaplastic lymphoma kinase and c-Met tyrosine ...

Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults. We found nothing new that affects the ...

Here we report a pediatric patient with relapsed and refractory AML with RAN-binding protein 2 (RANBP2)-ALK fusion with monosomy 7, who achieved complete remission (CR) after treatment with crizotinib ...

Previously demonstrated survival benefits of crizotinib (Xalkori, Pfizer Inc.) as an adjuvant treatment for advanced ALK-positive non-small cell lung cancer (ALK+NSCLC) did not extend to the setting ...